Clinical trials: BRONCHIAL ASTHMA
Asthma, Chronic Obstructive Pulmonary Disease
Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)
The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with…
- Trial name
- SALIF (NCT01424137)
- Testing
- Easyhaler type A, Easyhaler type B, Diskus inhaler
- Where
- 5 sites in Estonia, Finland
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Severe Asthma
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
To evaluate the pharmacokinetics, safety and immunogenicity of BAT2606 in healthy China male subjects.
- Trial name
- NCT05576454
- Testing
- Mepolizumab Injection (BAT2606 Injection), Mepolizumab Injection (EU-licensed Nucala), Mepolizumab Injection (US-licensed Nucala)
- Where
- China
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Severe Eosinophilic Asthma
Real World Study With Benralizumab in Severe Asthma in Switzerland
BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1…
- Trial name
- BEEPS (NCT03907137)
- Where
- 12 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Asthma
Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)
This study is an economic evaluation of Symbicort (Budesonide/formoterol) as maintenance and reliever therapy (SMART) versus its competitive alternatives.
- Trial name
- NCT00937066
- Where
- Colombia
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma
A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma
This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.
- Trial name
- NCT01479595
- Testing
- QBX258
- Where
- 20 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
- Trial name
- NCT05757102
- Testing
- FF/UMEC/VI, ELLIPTA, FF/VI
- Where
- 67 sites in United States, Argentina and 7 more
- Volunteers
- 138 people
- Sponsor
- GlaxoSmithKline
Asthma
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma.
- Trial name
- NCT00818454
- Testing
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Where
- 41 sites in United States
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Asthma
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, pharmacodynamics and safety of two formulations of Omalizumab (CMAB007 and Xolair) in healthy subjects.
- Trial name
- NCT04778137
- Testing
- Omalizumab
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Asthma, Bronchospasm
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered…
- Conditions
- Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01189396
- Testing
- A006, Proventil-HFA
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
To determine the safety and tolerability of MG-ZG122 in Chinese healthy adult subjects
- Trial name
- NCT05659927
- Testing
- MG-ZG122 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Allergic Asthma, Uncontrolled Moderate to Severe
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled…
- Trial name
- NCT05813470
- Testing
- Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
- Where
- 22 sites in Iran
- Volunteers
- 256 people
- Sponsor
- Cinnagen
Asthma
Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France
Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma
- Trial name
- SYMBIOSE (NCT00812357)
- Where
- 168 sites in France
- Volunteers
- 579 people
- Sponsor
- AstraZeneca
Severe Asthma
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such…
- Trial name
- NCT06196879
- Testing
- Verekitug (UPB-101)
- Where
- 155 sites in United States, Argentina and 13 more
- Volunteers
- 479 people
- Sponsor
- Upstream Bio Inc.
Asthma
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis.
- Trial name
- NCT06642961
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Asthma
Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects
The purpose of the study is to investigate the clinical effects of multiple (28 day) twice-daily doses of OC000459 in comparison to placebo on clinic lung function (FEV1) in mild to moderate asthmatics with an FEV1 of 60-80% of…
- Trial name
- NCT01057927
- Testing
- OC000459
- Where
- 16 sites in Russia
- Volunteers
- 132 people
- Sponsor
- Oxagen Ltd
Asthma
Multicentre Post-market Study of Ectoin® Inhalation Solution in Treatment of Asthma.
The goal of this multi-centre, prospective, open-label, single-arm, post-market clinical follow-up study is to further strengthen the already existing clinical evidence for supportive treatment and symptoms alleviation in asthma…
- Trial name
- EIL-AST (NCT05699941)
- Testing
- Ectoin® Inhalation Solution
- Where
- 5 sites in Poland
- Volunteers
- 204 people
- Sponsor
- Bitop AG
Asthma
FASENRA SCEI for Long-term Use
The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.
- Trial name
- NCT03588546
- Where
- 29 sites in Japan
- Volunteers
- 653 people
- Sponsor
- AstraZeneca
Asthma, Airway Inflammation
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation…
- Trial name
- NCT00635882
- Testing
- mometasone furoate/formoterol 100/10 mcg, mometasone furoate/formoterol 200/10 mcg, mometasone furoate/formoterol 400/10 mcg
- Volunteers
- 93 people
- Sponsor
- Organon and Co
Asthma
A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.
The purpose of this study is to demonstrate that the CHF 1535 (fixed combination of Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg) delivered via the NEXT Dry Powder Inhaler (DPI) does not show a greater…
- Trial name
- ADONE (NCT01191424)
- Testing
- CHF1535 NEXT DPI, BDP DPI and formoterol DPI
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.